News
EVO
1.560
+1.96%
0.030
Berenberg Bank Sticks to Their Hold Rating for Evotec (0IRF)
TipRanks · 2d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 5d ago
Weekly Report: what happened at EVO last week (0914-0918)?
Weekly Report · 6d ago
Evotec: The Market Seems Split On The Company's Prospects, Buy
Seeking Alpha · 6d ago
Weekly Report: what happened at EVO last week (0907-0911)?
Weekly Report · 09/14 09:43
Evotec’s Just – Evotec Biologics Starts Phase 1 Trial of Orthopoxvirus Antibodies for U.S. Biodefense
TipRanks · 09/09 10:48
Evotec initiates clinical trial evaluating JST-018
TipRanks · 09/09 09:15
Evotec Biologics Begins Phase 1 Trial For Orthopoxvirus Antibody Program
NASDAQ · 09/09 08:22
Evotec Subsidiary Just Biologics Moves JST-018 Orthopoxvirus Antibodies Into First-In-Human Phase 1 Study For Biodefense
Benzinga · 09/09 06:39
Weekly Report: what happened at EVO last week (0831-0904)?
Weekly Report · 09/07 09:40
Evotec, Plectonic Biotech announce immunotherapy research collaboration
TipRanks · 09/02 09:10
Evotec, Plectonic Enter Research Collaboration For T-Cell-Engaging Solid Tumour Therapies
NASDAQ · 09/02 07:00
H.C. Wainwright Sticks to Its Buy Rating for Evotec AG (EVO)
TipRanks · 09/01 08:36
Weekly Report: what happened at EVO last week (0824-0828)?
Weekly Report · 08/31 09:44
Weekly Report: what happened at EVO last week (0817-0821)?
Weekly Report · 08/24 09:44
Weekly Report: what happened at EVO last week (0810-0814)?
Weekly Report · 08/17 09:45
Analysts Are Bullish on Top Healthcare Stocks: Evotec AG (EVO), Taysha Gene Therapies (TSHA)
TipRanks · 08/14 15:30
Evotec AG Earnings Call: Weak 2026, Pipeline Hopes
TipRanks · 08/14 00:19
Evotec SE reports 1H results
Seeking Alpha · 08/13 19:02
Evotec Reports Second Quarter And First Half 2026 Results, Updates Full-Year Outlook; Stock Down
NASDAQ · 08/13 15:19
More
Webull provides a variety of real-time EVO stock news. You can receive the latest news about Evotec Ag through multiple platforms. This information may help you make smarter investment decisions.
About EVO
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.